- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02734706
Efficacy of a LRC™ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults
May 8, 2019 updated by: UAS Labs LLC
Efficacy of a Supplement Capsule Containing LRC™ (L. Reuteri NCIMB 30242) on Managing Cholesterol Levels in Adults
To investigate the effect of a supplement capsule containing LRC™ (L.
reuteri NCIMB 30242), taken twice daily with lunch and dinner (NLT 2.5E9 CFU per dose), versus placebo capsule on serum low density lipoprotein (LDL)-cholesterol in otherwise healthy hypercholesterolemic adults after 9 weeks of product consumption.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
111
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Synergize Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females aged 20 to 75 years.
- LDL-C ≥ 3.40 mmol/L at visits V0 and V2-1 (<15% variation between visits V0 and V2-1).
- TG < 4.00 mmol/L (checked at visits V0 and V2-1).
- BMI between 23.0 to 32.5 kg/m2.
- Subject understands and accepts to follow the dietary recommendations advisable for hypercholesterolemic patients (according to NCEP-ATP III guidelines)
- Judged by the investigators as compliant (>80%) with product consumption (check at V2-1), and motivated.
- Subjects taking stable doses of thyroid hormone and anti-hypertensive agents will be permitted, as long as these are continued equivalently throughout the duration of study.
- Agreement to maintain current level of physical activity throughout the study.
- If female, subject is not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation) OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System); Intrauterine devices; Vasectomy of partner.
- Voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Use of cholesterol lowering prescription drugs within the last 6 months.
- Use of plant sterols, omega 3, fish oil, soy protein, soluble oat fiber, psyllium seed husk, or other cholesterol lowering non-prescription supplements within last 1 month.
- History of chronic use of alcohol (>2 drinks/d).
- History of heavy smoking (≥20 cigarettes/d).
- Use of systemic antibodies, corticosteroids, androgens, or phenytoin.
- Immune-compromised subjects (e.g. AIDS, lymphoma, subjects undergoing long-term corticosteroid treatment).
- Subject having experienced any cardiovascular event (myocardial infarction, coronary artery bypass, or other major surgical procedures) in the last 6 months.
- Subjects with elevated LDL-C (≥ 3.40 mmol/L) and high (>20%) CVD risk estimated by the Framingham risk score.
- Previously diagnosed Type I or Type II diabetes or any other endocrine disorders such as adrenal insufficiency, Cushing's disease, hyperthyroidism, hypopituitarism or polycystic ovary syndrome.
- Subject receiving systemic treatment or topical treatment likely to interfere with evaluation of the study parameters.
- Subject currently involved in a clinical trial or in an exclusion period following participation in another clinical trial.
- History of angina, congestive heart failure, inflammatory bowel disease, pancreatitis, gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of active lesions, chemotherapy or surgery in the past year).
- Clinically significant abnormal laboratory results at screening.
- Chronic user of probiotics or fibre laxative (greater than 2 doses/wk), or stimulant laxatives.
- History of eating disorders.
- Exercise greater than 15 miles/wk or 4,000 kcal/wk.
- For female subjects: Pregnancy, breast feeding, or intent to get pregnant.
- Allergy or sensitivity to test product ingredients.
- Allergy or sensitivity to all 3 antibiotics (Clindamycin, Erythromycin and Ampicillin).
- Diagnosis of anemia or bleeding disorders
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LRC™ capsule
|
Twice per day (BID), 9 weeks
|
Placebo Comparator: Placebo capsule
|
Twice per day (BID), 9 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum LDL-cholesterol after 9 weeks of product consumption.
Time Frame: 9 weeks
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum LDL-cholesterol after 6 weeks of product consumption.
Time Frame: 6 weeks
|
6 weeks
|
Serum total cholesterol after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Serum HDL-cholesterol after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Serum non-HDL-cholesterol after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Serum triglycerides after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Serum apolipoprotein B-100 after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Serum hs-CRP after 9 weeks of product consumption.
Time Frame: 9 weeks
|
9 weeks
|
Plasma fibrinogen after 9 weeks of product consumption.
Time Frame: 9 weeks
|
9 weeks
|
Plasma homocysteine after 9 weeks of product consumption.
Time Frame: 9 weeks
|
9 weeks
|
GI health questionnaire score after 6 and 9 weeks of product consumption.
Time Frame: 6 and 9 weeks
|
6 and 9 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Actual)
November 1, 2018
Study Completion (Actual)
February 1, 2019
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
April 5, 2016
First Posted (Estimate)
April 12, 2016
Study Record Updates
Last Update Posted (Actual)
May 10, 2019
Last Update Submitted That Met QC Criteria
May 8, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15LCHU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineCompletedPrimary HypercholesterolemiaUnited States
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Merck Sharp & Dohme LLCTerminated
-
Danone JapanCompletedHealthy | Mild HypercholesterolemiaJapan
Clinical Trials on LRC™ capsule
-
Beijing Friendship HospitalNot yet recruiting
-
University of WashingtonNational Institute of Mental Health (NIMH); University of Pennsylvania; Washington... and other collaboratorsActive, not recruitingPerinatal DepressionUnited States
-
Micropharma LimitedCompletedHypercholesterolemiaCzech Republic
-
Celero Systems, Inc.Recruiting
-
Medtronic - MITGCompletedColonic Diseases | Bowel DiseasesUnited States
-
Medtronic - MITGCompletedColonic Diseases | and Large Bowel DiseasesSpain, Sweden, Germany, Belgium, France, Italy, Netherlands
-
Centre Hospitalier Universitaire de NiceCompletedCancer | Adenomatous PolypsFrance, Italy
-
UAS Labs LLCCompleted
-
Medtronic - MITGCompleted